Rational Innovation

New technologies are announced almost daily, so what makes SynDevRx different?  Our technology increases the activity of small molecule drugs, allowing for reduced doses, lower exposure and lower risk of toxicities.

We believe our compounds are the next generation of drug therapies. They combine highly active moieties conjugated to a stable, bio-compatible polymer using proprietary techniques. Restricting drug release to intra-cellular environments concentrates activity where needed while reducing the risk of toxicities.

For more information, please contact:

Jim Shanahan

VP Business Development
617.401.3110 (office)


NB: SynDevRx is not affiliated with Children's Hospital Boston, and has no development program associated with Children's Hospital.